期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

联合用药治疗妊娠期肝内胆汁瘀积症对母婴结局的影响 被引量：7

下载PDF
导出
摘要 目的分析思美泰(S-adenosyl-L-methione,SAMe)联合熊去氧胆酸(ursodeoxycholic acid,UDCA)治疗妊娠期肝内胆汁瘀积症(intrahepatic cholestasis of pregnancy,ICP)的疗效。方法将158例ICP患者随机分2组,A组用SAMe联合UDCA,B组单用SAMe,比较2组疗效及对妊娠结局的影响。结果 2组都能明显改善患者症状、血生化指标和妊娠结局(P<0.05),A组的疗效明显优于B组(P<0.05),且A组起效快于B组(P<0.05)。结论 SAMe联合UDCA治疗ICP较单用SAMe疗效满意。
作者 刘荣
机构地区 浙江省湖州市妇幼保健院妇产科
出处 《河北医科大学学报》 CAS 2013年第5期585-587,共3页 Journal of Hebei Medical University
关键词 胆汁淤积症 肝内 思美泰 熊去氧胆酸 治疗结果
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献2

二级参考文献20

  • 1曹泽毅.《中华妇产科学》[M](第1版)[M].北京:人民卫生出版社,1999.500-507.
  • 2Frezza M, Surrenti C, ManziUo G, Fiaccadori F, Bortolini M, Di Padova C, Oral S.adenosylmethionine in the symptomatic treatment of mtrahepatic cholestasis. A double-blind, placebo-controlled study[J]. Gastroenterology, 1990; 99(1 ) : 211 - 215.
  • 3Alma.rio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis [J ]. Drugs,1990; 40 (Suppl 3) : 111-123.
  • 4Jadad AR, Moore A, Carroll D. Assessing the quality of reports ofrandomized chnical trials: Is bhnding necessary [ J ]. Control Clinical Trials, 1996; 17(1): 1-12.
  • 5Bonessio L, Ciardo A, Spina V, Morini A. Intrahepatic cholestasis in pregnancy[J]. Clin Ter, 1996; 147(7-8) : 377 -384.
  • 6Ribalta J, Reyes H, Gonzalez MC. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results[J]. Hepatology, 1991; 13(6): 1 084-1 089.
  • 7Frezza M, Pozzato G, Chiesa L. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methioninead ministration[J]. Hepatology, 1984; 4(2): 274-278.
  • 8Floreani A, Patemoster D, Melis A, Grella PV. S-adenosyl-1-methionine versus ursodeox-ycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial[ J ], Eur J Obstet Gynecol Reprod Biol, 1996 ;67 ( 2 ) :109 - 113.
  • 9Frezza M, Tritapepe R, Pozzato G, Di Padova C. Prevention of S-adenosyl-l-methionine of estrogen-induced hepatobiliary toxicity in susceptible women[J]. Am J C, astroenterol,1988; 83(10) : 1 098 -1102.
  • 10Nicastri PL, Diaferia A, Tartagni M, Loizzi P, Fanelli M. A randomised placebo-controUed trial of ursodeoxycholic acid and Sadenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy[J]. Br J Obstet Gynaecol, 1998 ; 105( 11 ) : 1 205 - 1207.

共引文献69

同被引文献64

  • 1Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receivingursodeoxycholic acid therapy[J]. Gastroeaterolgoy, 201S, 149 (7) :1804-1812,e4.
  • 2Kramp KH, van Det MJ, Totte ER, et al. Ergonomic assessment of the French and American position for laparoscopic choleeysteetomy in the MIS Suite E J~. Surg Endosc,2014,28(5) :1571-1578.
  • 3Deitz KL,Makielski KM, Williams JM, et aL Effect of 6- 8 weeks of oral ursodeoxycholic acid administration on serum concentrations of fasting and postprandial bile acids and biochemical analytes in healthy dogs[J']. Vet Clin Pathol, 2015,44(3) :431-436.
  • 4Zha J, Badri PS, Ding B, et al. Drug interactions between hepatoprotective agents ursodeoxycholic acid or glycyrrhizin and ombitasvir/paritaprevir/ritonavir in healthy japanese subjects[J]. Clin Ther, 2015,37 (!) : 2560- 2571.
  • 5Krawczyk M, Rusticeanu M,Granhage F,et al. Analysis of the common vasoactive intestinal peptide receptor 1 polymorphismin gallstone patients[J3. J Gastrointetin Liver Dis,2010,19(1):273-277.
  • 6Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receivingursodeoxycholic acid therapy[J]. Gastroeaterolgoy, 201S, 149 (7) :1804-1812,e4.
  • 7Kramp KH, van Det MJ, Totte ER, et al. Ergonomic assessment of the French and American position for laparoscopic choleeysteetomy in the MIS Suite E J~. Surg Endosc,2014,28(5) :1571-1578.
  • 8Deitz KL,Makielski KM, Williams JM, et aL Effect of 6- 8 weeks of oral ursodeoxycholic acid administration on serum concentrations of fasting and postprandial bile acids and biochemical analytes in healthy dogs[J']. Vet Clin Pathol, 2015,44(3) :431-436.
  • 9Zha J, Badri PS, Ding B, et al. Drug interactions between hepatoprotective agents ursodeoxycholic acid or glycyrrhizin and ombitasvir/paritaprevir/ritonavir in healthy japanese subjects[J]. Clin Ther, 2015,37 (1) : 2560- 2571.
  • 10Krawczyk M, Rusticeanu M,Granhage F,et al. Analysis of the common vasoactive intestinal peptide receptor 1 polymorphismin gallstone patients[J3. J Gastrointetin Liver Dis,2010,19(1):273-277.

引证文献7

二级引证文献43

河北医科大学学报
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部